All In Biotech

Drug Trial Radar · NCT05522868

SB17170 Phase 1 Clinical Trial in Solid Tumors

An Open-label, Multicenter, Phase 1 Clinical Trial to Evaluate MTD, Safety, PK/PD and Preliminary Anti-tumor Activity of SB17170 in Patients With Locally Advanced or Metastatic Solid Tumors Who Have Failed Standard of Care

Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Oct 17, 2022

Primary completion

Jun 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
SPARK BiopharmaIndustry
Sponsor type
Industry
First posted
Aug 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 Open-label, multicenter, dose escalation, dose expansion study

Conditions

  • Solid Tumor

Interventions

  • SB17170Drug

    SB17170 capsules, Oral administration 21days/cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of SB17170Time frame: At the end of Cycle 1 (each cycle is 21 days)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea · Not yet recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Not yet recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.